BioElectronics Corporation (OTC: BIEL) announced today the imminent commercial launch of ActiPatch in Taiwan by its appointed distributor, Aphrodite Medical Group. This move marks a significant expansion for the company's drug-free pain therapy into the Asian market.
ActiPatch is a US FDA-cleared, non-invasive medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and is designed for extended wear, including during sleep, offering a practical alternative to pharmaceuticals. The initial shipment of units has been completed, positioning ActiPatch for a coordinated market launch in Q2 2026, focusing initially on musculoskeletal pain management with potential for expansion into other clinical applications.
Kelly Whelan, CEO of BioElectronics Corporation, stated, "The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan. Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way." Aphrodite Medical Group, a well-established healthcare provider in Taiwan with a broad clinical footprint, will lead market introduction, physician engagement, and patient access initiatives across its network and affiliated channels.
Yang Pei-Hsien, Vice President of Aphrodite Medical Group, commented, "We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies. This technology aligns with the growing demand for safe, effective, and drug-free pain management options." The launch reinforces BioElectronics' strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies.
BioElectronics Corporation (OTC: BIEL) is a medical device company focused on the development and commercialization of bioelectronic therapies. Its products, including ActiPatch and RecoveryRx, are FDA-cleared, non-invasive, drug-free devices designed to treat pain and support recovery using pulsed shortwave technology. Aphrodite Medical Group is a Taiwan-based healthcare organization offering a comprehensive range of medical and wellness services through a network of clinics and providers, focused on delivering advanced technologies and high-quality care.
For more information, see the original release on NewMediaWire.
